Literature DB >> 26021203

Cost-Analyses Studies in Barrett's Esophagus: What Is Their Utility?

Lauren B Gerson1.   

Abstract

Approximately 10% to 15% of the chronic gastroesophageal reflux disease population is at risk for the development of Barrett's esophagus, particularly in the setting of other risk factors, including male gender, Caucasian race, age more than 50, and central obesity. The risk of cancer progression for patients with nondysplastic BE has been estimated to be approximately 0.2% to 0.5% per year. Given these low progression rates and the high cost of endoscopic surveillance, cost-effectiveness analyses in this area are useful to determine appropriate resource allocation.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Ablation therapy; Barrett’s esophagus; Cost-effectiveness; Health-state utilities; Markov model

Mesh:

Year:  2015        PMID: 26021203     DOI: 10.1016/j.gtc.2015.02.011

Source DB:  PubMed          Journal:  Gastroenterol Clin North Am        ISSN: 0889-8553            Impact factor:   3.806


  2 in total

Review 1.  Systematic Analysis and Critical Appraisal of the Quality of the Scientific Evidence and Conflicts of Interest in Practice Guidelines (2005-2013) for Barrett's Esophagus.

Authors:  Joseph D Feuerstein; Natalia E Castillo; Mona Akbari; Edward Belkin; Jeffrey J Lewandowski; Christine M Hurley; Samuel Lloyd; Daniel A Leffler; Adam S Cheifetz
Journal:  Dig Dis Sci       Date:  2016-06-15       Impact factor: 3.199

2.  Combined EsophaCap cytology and MUC2 immunohistochemistry for screening of intestinal metaplasia, dysplasia and carcinoma.

Authors:  Zhongren Zhou; Irina Kalatskaya; Donna Russell; Norman Marcon; Maria Cirocco; Paul M Krzyzanowski; Cathy Streutker; Hua Liang; Virginia R Litle; Tony E Godfrey; Lincoln Stein
Journal:  Clin Exp Gastroenterol       Date:  2019-05-15
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.